Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Clinical and Translational Allergy
|
April 10, 2019
Cofactors of wheat-dependent exercise-induced anaphylaxis do not increase highly individual gliadin absorption in healthy volunteers
Katharina Anne Scherf, Ann-Christin Lindenau, Luzia Valentini, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
March 17, 2025
Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real-life retrospective study
Dirk Tomsitz, Petra Zimmermann, Wolfgang G Kunz, et al.
Cancer Immunology, Immunotherapy : CII
|
May 16, 2022
Checkpoint-inhibitor induced Polyserositis with Edema
Sarah Zierold, Larissa Semra Akcetin, Eva Gresser, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 29, 2024
Brief Communication: Treatment Outcomes for Advanced Melanoma of Unknown Primary Compared With Melanoma With Known Primary
Oana-Diana Persa, Jessical Cecile Hassel, Theresa Steeb, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
January 22, 2026
Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy
Kristine E Mayer, Jessica C Hassel, Jannik Sambale, et al.
Journal for Immunotherapy of Cancer
|
June 12, 2026
Extracorporeal photopheresis versus systemic immunosuppression for treatment of immune-related adverse events: clinical outcomes from the prospective two-arm PRIA study
Lisa Wein, Carolin Ertl, Theresa Ruf, et al.
International Journal of Cancer
|
September 17, 2015
Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice
Eva Distler, Jana Albrecht, Ariane Brunk, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2024
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors
Theresa Ruf, Rafaela Kramer, Andrea Forschner, et al.
Cancers
|
July 14, 2023
Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study
Dirk Tomsitz, Theresa Ruf, Markus Heppt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Clinical and Translational Allergy
|
April 10, 2019
Cofactors of wheat-dependent exercise-induced anaphylaxis do not increase highly individual gliadin absorption in healthy volunteers
Katharina Anne Scherf, Ann-Christin Lindenau, Luzia Valentini, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
March 17, 2025
Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real-life retrospective study
Dirk Tomsitz, Petra Zimmermann, Wolfgang G Kunz, et al.
Cancer Immunology, Immunotherapy : CII
|
May 16, 2022
Checkpoint-inhibitor induced Polyserositis with Edema
Sarah Zierold, Larissa Semra Akcetin, Eva Gresser, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 29, 2024
Brief Communication: Treatment Outcomes for Advanced Melanoma of Unknown Primary Compared With Melanoma With Known Primary
Oana-Diana Persa, Jessical Cecile Hassel, Theresa Steeb, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
January 22, 2026
Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy
Kristine E Mayer, Jessica C Hassel, Jannik Sambale, et al.
Journal for Immunotherapy of Cancer
|
June 12, 2026
Extracorporeal photopheresis versus systemic immunosuppression for treatment of immune-related adverse events: clinical outcomes from the prospective two-arm PRIA study
Lisa Wein, Carolin Ertl, Theresa Ruf, et al.
International Journal of Cancer
|
September 17, 2015
Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice
Eva Distler, Jana Albrecht, Ariane Brunk, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2024
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors
Theresa Ruf, Rafaela Kramer, Andrea Forschner, et al.
Cancers
|
July 14, 2023
Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study
Dirk Tomsitz, Theresa Ruf, Markus Heppt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma
Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
Page
of 4